Compounds of formula (I) wherein ring B is selected from the group consisting of Formula (B-a) and Formula (B-bc) as human cytidine triphosphate synthase 1 ( CTPS1) inhibitors for the treatment of proliferative diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 129 to page 302; examples; biological examples 1 and 2; tables 1-17). Specific examples are e.g.: N-(4-(5-Chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido) pyrimidin-4-yl)butanamide (Formula P1) or 1-(2-(Cyclopropanesulfonamido)pyrimidin-4-yl)-N-(4-(6- ethoxypyrazin-2-yl)phenyl)cyclopentanecarboxamide (Formula P2).
式(I)的化合物,其中环B选自由Formula(B-a)和Formula(B-bc)所组成的群体,作为人类
胞嘧啶三磷酸合成酶1(CTPS1)
抑制剂,用于治疗增殖性疾病,例如癌症,如白血病和淋巴瘤,例如炎症性皮肤病如牛皮癣,例如多发性硬化症。本说明披露了示例化合物的合成和表征,以及其药理学数据(例如,第129页至第302页;示例;
生物学示例1和2;表1-17)。具体示例包括:N-(4-(5-
氯吡啶-3-基)苯基)-2-(2-(环丙磺酰胺基)
嘧啶-4-基)丁酰胺(Formula P1)或1-(2-(环丙磺酰胺基)
嘧啶-4-基)-N-(4-(6-乙氧
吡嗪-2-基)苯基)
环戊烷甲酰胺(Formula P2)。